(HELE) Helen of Troy - Overview
Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NASDAQ (USA) | Market Cap: 567m USD | Total Return: -23.4% in 12m
Industry Rotation: +9.5
Avg Turnover: 16.3M
EPS Trend: -88.5%
Qual. Beats: 0
Rev. Trend: -98.6%
Qual. Beats: 1
Warnings
Interest Coverage Ratio -6.4 is critical
Choppy
Tailwinds
No distinct edge detected
Helen of Troy Limited is a diversified global consumer products company headquartered in El Paso, Texas. The company operates through two primary segments: Home & Outdoor and Beauty & Wellness. Its portfolio includes well-known brands such as OXO, Hydro Flask, Osprey, Vicks, Braun, Honeywell, and PUR, covering categories ranging from kitchenware and outdoor gear to health monitoring and professional hair care.
The business model relies on a multi-channel distribution strategy, selling through mass merchandisers, e-commerce platforms, specialty retailers, and direct-to-consumer channels. As a player in the Household Appliances sub-industry, the company maintains a mix of owned brands and licensed trademarks to capture market share across different price points and consumer demographics. Investors looking for deeper insights into these brand valuations should consult ValueRay for further analysis.
Operating internationally across North America, Europe, the Middle East, and Asia, the company focuses on high-use consumer essentials and technical outdoor equipment. This sector is characterized by cyclical demand for durable goods combined with steady replacement cycles for health and wellness consumables.
- Consumer demand for Hydro Flask and Osprey impacts Home and Outdoor segment revenue
- Seasonal flu and cold severity drives sales of Vicks and Braun wellness products
- Elevated inventory levels and promotional discounting pressure consolidated gross profit margins
- Higher interest rates increase debt servicing costs for recent strategic brand acquisitions
- Supply chain efficiency and Project Pegasus cost savings initiatives influence operating margins
| Net Income: -899.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 10.04 > 1.0 |
| NWC/Revenue: 20.18% < 20% (prev 24.40%; Δ -4.21% < -1%) |
| CFO/TA 0.13 > 3% & CFO 270.5m > Net Income -899.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.0m) vs 12m ago 0.43% < -2% |
| Gross Margin: 45.66% > 18% (prev 0.48%; Δ 4.52k% > 0.5%) |
| Asset Turnover: 68.08% > 50% (prev 60.91%; Δ 7.17% > 0%) |
| Interest Coverage Ratio: -6.39 > 6 (EBITDA TTM -315.4m / Interest Expense TTM 57.7m) |
| A: 0.17 (Total Current Assets 865.5m - Total Current Liabilities 505.0m) / Total Assets 2.12b |
| B: 0.20 (Retained Earnings 412.8m / Total Assets 2.12b) |
| C: -0.14 (EBIT TTM -368.7m / Avg Total Assets 2.62b) |
| D: 0.31 (Book Value of Equity 413.2m / Total Liabilities 1.32b) |
| Altman-Z'' Score: 1.14 = BB |
| DSRI: 0.90 (Receivables 366.7m/434.1m, Revenue 1.79b/1.91b) |
| GMI: 1.05 (GM 45.66% / 47.93%) |
| AQI: 0.72 (AQ_t 0.42 / AQ_t-1 0.59) |
| SGI: 0.94 (Revenue 1.79b / 1.91b) |
| TATA: -0.55 (NI -899.0m - CFO 270.5m) / TA 2.12b) |
| Beneish M-Score: -3.84 (Cap -4..+1) = AAA |
Over the past week, the price has changed by +6.92%, over one month by +21.08%, over three months by +29.32% and over the past year by -23.38%.
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 29.3 | 22.5% |
P/S = 0.3172
P/B = 0.72
P/EG = 0.9718
Revenue TTM = 1.79b USD
EBIT TTM = -368.7m USD
EBITDA TTM = -315.4m USD
Long Term Debt = 755.8m USD (from longTermDebt, last quarter)
Short Term Debt = 25.0m USD (from shortTermDebt, last quarter)
Debt = 833.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 814.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.38b USD (566.6m + Debt 833.7m - CCE 18.9m)
Interest Coverage Ratio = -6.39 (Ebit TTM -368.7m / Interest Expense TTM 57.7m)
EV/FCF = 5.15x (Enterprise Value 1.38b / FCF TTM 268.5m)
FCF Yield = 19.43% (FCF TTM 268.5m / Enterprise Value 1.38b)
FCF Margin = 15.03% (FCF TTM 268.5m / Revenue TTM 1.79b)
Net Margin = -50.33% (Net Income TTM -899.0m / Revenue TTM 1.79b)
Gross Margin = 45.66% ((Revenue TTM 1.79b - Cost of Revenue TTM 970.6m) / Revenue TTM)
Gross Margin QoQ = 44.61% (prev 46.87%)
Tobins Q-Ratio = 0.65 (Enterprise Value 1.38b / Total Assets 2.12b)
Interest Expense / Debt = 1.55% (Interest Expense 12.9m / Debt 833.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -291.3m (EBIT -368.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.71 (Total Current Assets 865.5m / Total Current Liabilities 505.0m)
Debt / Equity = 1.04 (Debt 833.7m / totalStockholderEquity, last quarter 798.2m)
Debt / EBITDA = -2.58 (negative EBITDA) (Net Debt 814.8m / EBITDA -315.4m)
Debt / FCF = 3.04 (Net Debt 814.8m / FCF TTM 268.5m)
Total Stockholder Equity = 951.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.26% (Net Income -899.0m / Total Assets 2.12b)
RoE = -94.52% (Net Income TTM -899.0m / Total Stockholder Equity 951.1m)
RoCE = -21.60% (EBIT -368.7m / Capital Employed (Equity 951.1m + L.T.Debt 755.8m))
RoIC = -16.09% (negative operating profit) (NOPAT -291.3m / Invested Capital 1.81b)
WACC = 5.63% (E(566.6m)/V(1.40b) * Re(12.12%) + D(833.7m)/V(1.40b) * Rd(1.55%) * (1-Tc(0.21)))
Discount Rate = 12.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -6.67 | Cagr: -1.53%
[DCF] Terminal Value 82.10% ; FCFF base≈194.3m ; Y1≈138.2m ; Y5≈74.1m
[DCF] Fair Price = 64.54 (EV 2.32b - Net Debt 814.8m = Equity 1.50b / Shares 23.3m; r=6.0% [WACC]; 5y FCF grow -33.98% → 3.0% )
EPS Correlation: -88.50 | EPS CAGR: -23.44% | SUE: 0.44 | # QB: 0
Revenue Correlation: -98.58 | Revenue CAGR: -4.83% | SUE: 1.10 | # QB: 1
EPS current Quarter (2026-05-31): EPS=0.01 | Chg30d=N/A | Revisions=+0% | Analysts=4
EPS next Quarter (2026-08-31): EPS=0.49 | Chg30d=+54.04% | Revisions=+43% | Analysts=4
EPS current Year (2027-02-28): EPS=3.52 | Chg30d=+4.95% | Revisions=+14% | GrowthEPS=-0.9% | GrowthRev=+0.2%
EPS next Year (2028-02-29): EPS=4.06 | Chg30d=+1.33% | Revisions=+0% | GrowthEPS=+15.5% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: +43%